Palbociclib

Generic Name
Palbociclib
Brand Names
Ibrance
Drug Type
Small Molecule
Chemical Formula
C24H29N7O2
CAS Number
571190-30-2
Unique Ingredient Identifier
G9ZF61LE7G
Background

Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.
...

Indication

Palbociclib is indicated in combination with letrozole as initial endocrine-based therapy for the treatment of human epidermal growth factor receptor type 2 (HER2)-negative and hormone receptor(HR)-positive tumors in adult patients with advanced/metastatic breast cancer. It is as well approved in combination with fulvestrant in patients with disease progress...

Associated Conditions
Advanced Breast Cancer, Metastatic Breast Cancer, Refractory, advanced Breast cancer, Refractory, metastatic Breast cancer
Associated Therapies
-
Clinical Trials
Related News

Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer

Phase 2
Completed
Conditions
Metastatic Breast Cancer
Interventions
Drug: Palbociclib
Drug: Fulvestrant
First Posted Date
2015-09-01
Last Posted Date
2024-02-26
Lead Sponsor
ETOP IBCSG Partners Foundation
Target Recruit Count
124
Registration Number
NCT02536742
Locations
🇧🇪

CHU Liege, Liège, Belgium

🇧🇪

Cliniques Universitaires Saint-Luc, Brussels, Belgium

🇮🇹

Azienda USL4 Prato, Prato, Italy

and more 16 locations

"Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "

First Posted Date
2015-08-21
Last Posted Date
2020-07-15
Lead Sponsor
Fondazione Michelangelo
Target Recruit Count
102
Registration Number
NCT02530424
Locations
🇮🇹

Istituto Europeo di Oncologia, Milano, MI, Italy

🇮🇹

Policlinico Sant'Orsola Malpighi, Bologna, BO, Italy

🇮🇹

Azienda Ospedaliero Universitaria di Ferrara - Arcispedale S. Anna, Ferrara, FE, Italy

and more 4 locations

Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved

Phase 2
Completed
Conditions
Oligodendroglioma
Oligoastrocytoma
Interventions
Drug: Palbociclib
First Posted Date
2015-08-21
Last Posted Date
2024-11-22
Lead Sponsor
Grupo Español de Investigación en Neurooncología
Target Recruit Count
34
Registration Number
NCT02530320
Locations
🇪🇸

Hospital Insular de Canarias, Las Palmas de Gran Canaria, Las Palmas, Spain

🇪🇸

Hospital Son Espases, Palma de Mallorca, Mallorca, Spain

🇪🇸

Hospital Clínic de Barcelona, Barcelona, Spain

and more 8 locations

PALbociclib CoLlaborative Adjuvant Study

Phase 3
Active, not recruiting
Conditions
Breast Cancer
Interventions
Drug: Palbociclib
Drug: Standard Adjuvant Endocrine Therapy
First Posted Date
2015-07-31
Last Posted Date
2024-01-24
Lead Sponsor
Alliance Foundation Trials, LLC.
Target Recruit Count
5796
Registration Number
NCT02513394
Locations
🇺🇸

Hematology Oncology Associates of Central New York - East Syracuse, East Syracuse, New York, United States

🇺🇸

Kaiser Permanente Sunset Medical Center, Los Angeles, California, United States

🇺🇸

University of Pittsburgh Cancer Institute- Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

and more 431 locations

Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC

First Posted Date
2015-07-17
Last Posted Date
2021-04-06
Lead Sponsor
Pfizer
Target Recruit Count
76
Registration Number
NCT02501902
Locations
🇺🇸

UC San Diego Medical Center - La Jolla (Thornton Hospital), La Jolla, California, United States

🇺🇸

UC San Diego Moores Cancer Center - Investigational Drug Services, La Jolla, California, United States

🇺🇸

Anschutz Cancer Pavilion, Aurora, Colorado, United States

and more 23 locations

Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer

Phase 1
Active, not recruiting
Conditions
Advanced Breast Cancer
Interventions
Drug: Palbociclib
Drug: Letrozole
First Posted Date
2015-07-15
Last Posted Date
2024-09-30
Lead Sponsor
Pfizer
Target Recruit Count
26
Registration Number
NCT02499146
Locations
🇨🇳

The first hospital of jilin university, Changchun, Jilin, China

🇨🇳

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China

🇨🇳

Beijing Cancer Hospital/Oncology department, Beijing, Beijing, China

and more 4 locations

Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer

First Posted Date
2015-07-15
Last Posted Date
2023-09-08
Lead Sponsor
Pfizer
Target Recruit Count
125
Registration Number
NCT02499120
Locations
🇯🇵

Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan

🇺🇸

Henry Joyce Cancer Clinic, Nashville, Tennessee, United States

🇯🇵

Aichi cancer center Central hospital, Nagoya, Aichi, Japan

and more 68 locations

Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer

First Posted Date
2015-07-08
Last Posted Date
2024-12-09
Lead Sponsor
MedSIR
Target Recruit Count
486
Registration Number
NCT02491983
Locations
🇪🇸

MedSIR investigative site B, Zaragoza, Spain

🇬🇧

MedSIR investigative site, Truro, United Kingdom

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2
Active, not recruiting
Conditions
Advanced Malignant Solid Neoplasm
Breast Carcinoma
Cervical Carcinoma
Liver Carcinoma
Malignant Uterine Neoplasm
Recurrent Gastric Carcinoma
Recurrent Head and Neck Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Prostate Carcinoma
Recurrent Rectal Carcinoma
Interventions
Drug: Afatinib
Drug: Capivasertib
Drug: Binimetinib
Drug: Adavosertib
Procedure: Biospecimen Collection
Other: Cytology Specimen Collection Procedure
Drug: Afatinib Dimaleate
Drug: Dabrafenib
Drug: Defactinib
Drug: Fexagratinib
Drug: Dasatinib
Drug: Ipatasertib
Procedure: Biopsy
Drug: Crizotinib
Drug: Dabrafenib Mesylate
Drug: Taselisib
Drug: Sapanisertib
Drug: PI3K-beta Inhibitor GSK2636771
Drug: Defactinib Hydrochloride
Drug: Palbociclib
Biological: Nivolumab
Drug: Copanlisib
Drug: Ulixertinib
Biological: Trastuzumab Emtansine
Drug: Copanlisib Hydrochloride
Biological: Relatlimab
Procedure: Computed Tomography
Drug: Trametinib
Biological: Pertuzumab
Drug: Erdafitinib
Procedure: Radiologic Examination
Procedure: Multigated Acquisition Scan
Drug: Larotrectinib
Procedure: Echocardiography
Drug: Osimertinib
Biological: Trastuzumab
Drug: Larotrectinib Sulfate
Other: Laboratory Biomarker Analysis
Procedure: Magnetic Resonance Imaging
Drug: Vismodegib
Drug: Sunitinib Malate
Procedure: Radionuclide Imaging
First Posted Date
2015-06-08
Last Posted Date
2024-12-19
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
6452
Registration Number
NCT02465060
Locations
🇺🇸

Alaska Women's Cancer Care, Anchorage, Alaska, United States

🇺🇸

Anchorage Oncology Centre, Anchorage, Alaska, United States

🇺🇸

Katmai Oncology Group, Anchorage, Alaska, United States

and more 1416 locations

Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer

First Posted Date
2015-05-19
Last Posted Date
2024-04-18
Lead Sponsor
SOLTI Breast Cancer Research Group
Target Recruit Count
73
Registration Number
NCT02448420
Locations
🇪🇸

ICO Hospitalet, Barcelona, Spain

🇪🇸

Hospital Universitario Virgen del Rocio, Sevilla, Spain

🇪🇸

Hospital Clinico Universitario de Valencia, Valencia, Spain

and more 32 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy